Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients Under Guselkumab Treatment: A Long-Term Real-Life Experience

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Sep 14

PMID 39274388

Authors

Lorenzo Marcelli

Alfredo Belcastro

Marina Talamonti

Claudia Paganini

Angela Fico

Lorenzo Savastano

Cosimo Di Raimondo

Laura Vellucci

Luca Bianchi

Marco Galluzzo

Affiliations

Soon will be listed here.

Abstract

The term "super responder" identifies a group of patients who exhibit a rapid and optimal response to biological treatment compared to the overall treated population. The primary objective of our study is to characterize this subgroup of patients to enable the early identification of those who will respond most effectively to the proposed treatment while also evaluating clinical efficacy. This retrospective study evaluated 232 patients treated with guselkumab in monotherapy for at least 20 weeks between November 2018 and November 2023. Patients were divided into two groups: those who achieved complete clear skin (PASI = 0) during the first 20 weeks of treatment were defined as super responders (SRe) and non-super responders (nSRe) were the remaining patients. PASI was assessed at weeks 0, 4, and subsequently every eight weeks. Predictors of the SRe status were evaluated by univariate and multivariate logistic regression analyses. The univariate analyses showed that patients with psoriatic arthritis at the baseline, bio-naïve patients, or those who had not received an interleukin (IL) 17 inhibitor as their last therapy before guselkumab administration were more likely to be super responders to the proposed treatment. Multivariate logistic analysis models suggested that the combination of psoriatic arthritis at the baseline and the bio-naïve condition was the strongest predictive model for the SRe status. At week 204, the main difference between the two groups concerned the achievement of PASI100, maintained by 86.8 of SRe compared to 62.8% of nSRe. The efficacy and safety of guselkumab are confirmed in our real-life experience. Identifying the SRe status will undoubtedly play a role in clinical practice and the therapeutic decision-making algorithm.

References

Megna M, Potestio L, Fabbrocini G, Ruggiero A . Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. Psoriasis (Auckl). 2022; 12:205-212. PMC: 9292056. DOI: 10.2147/PTT.S372262. View

Hugo J, Kojanova M, Turkova B, Gkalpakiotis S . Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry. Dermatol Ther (Heidelb). 2023; 13(3):787-801. PMC: 9890420. DOI: 10.1007/s13555-023-00893-4. View

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke W . The role of IL-23 and the IL-23/T 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(10):1616-1626. PMC: 5697699. DOI: 10.1111/jdv.14433. View

Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan C . Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. J Clin Med. 2020; 9(7). PMC: 7408922. DOI: 10.3390/jcm9072170. View

Griffiths C, Armstrong A, Gudjonsson J, Barker J . Psoriasis. Lancet. 2021; 397(10281):1301-1315. DOI: 10.1016/S0140-6736(20)32549-6. View

Guo J, Zhang H, Lin W, Lu L, Su J, Chen X . Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023; 8(1):437. PMC: 10679229. DOI: 10.1038/s41392-023-01655-6. View

Giordano S, Dapavo P, Ortoncelli M, Stroppiana E, Verrone A, Quaglino P . Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. J Clin Med. 2023; 12(24). PMC: 10743732. DOI: 10.3390/jcm12247503. View

Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A . Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Clin Med. 2024; 13(2). PMC: 10816779. DOI: 10.3390/jcm13020495. View

Langley R, Tsai T, Flavin S, Song M, Randazzo B, Wasfi Y . Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2017; 178(1):114-123. DOI: 10.1111/bjd.15750. View

10.

Teng M, Bowman E, McElwee J, Smyth M, Casanova J, Cooper A . IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015; 21(7):719-29. DOI: 10.1038/nm.3895. View

11.

Reich K, Gordon K, Strober B, Armstrong A, Miller M, Shen Y . Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021; 185(6):1146-1159. DOI: 10.1111/bjd.20568. View

12.

Galluzzo M, Marcelli L, Fico A, Bianchi L, Talamonti M . Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series. Skin Health Dis. 2024; 4(1):e289. PMC: 10831554. DOI: 10.1002/ski2.289. View

13.

Galluzzo M, Marcelli L, Vellucci L, Paganini C, Maffei V, Tofani L . Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023; 23(4):371-381. DOI: 10.1080/14712598.2023.2194485. View

14.

Schakel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P . Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023; 37(10):2016-2027. DOI: 10.1111/jdv.19236. View

15.

Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M . Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). Front Immunol. 2024; 14:1341708. PMC: 10808601. DOI: 10.3389/fimmu.2023.1341708. View

16.

Oppmann B, Lesley R, Blom B, Timans J, Xu Y, Hunte B . Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13(5):715-25. DOI: 10.1016/s1074-7613(00)00070-4. View

17.

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

18.

Eyerich K, Weisenseel P, Pinter A, Schakel K, Asadullah K, Wegner S . IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021; 11(9):e049822. PMC: 8438891. DOI: 10.1136/bmjopen-2021-049822. View

19.

Choi S, Oh S, Yoon H . Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis. Ann Dermatol. 2022; 34(3):173-181. PMC: 9171179. DOI: 10.5021/ad.2022.34.3.173. View

20.

Herranz-Pinto P, Alonso-Pacheco M, Feltes-Ochoa R, Mayor-Ibarguren A, Servera-Negre G, Busto-Leis J . Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation. Clin Drug Investig. 2023; 43(7):517-527. PMC: 10374766. DOI: 10.1007/s40261-023-01280-9. View